Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening

Edna Keeney; Howard H Z Thom; Emma L Turner; Richard M Martin; Sabina Sanghera

doi:10.1007/s40273-021-01062-1

Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening

Edna Keeney, Howard H Z Thom, Emma L Turner, Richard M Martin, Sabina Sanghera

Research output: Contribution to journal › Comment/debate (Academic Journal) › peer-review

Original language	English
Pages (from-to)	969-970
Number of pages	2
Journal	PharmacoEconomics
Volume	39
Issue number	8
Early online date	17 Jul 2021
DOIs	https://doi.org/10.1007/s40273-021-01062-1
Publication status	Published - Aug 2021

Bibliographical note

Funding Information:
This work was funded by Cancer Research UK and the UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326, and C18281/A15064, C18281/A24432). SS is funded by a National Institute for Health Research (NIHR) fellowship (PDF-2017-10-008). HT and RMM were supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funding source was not involved in the design of the study, the collection, analysis and interpretation of data or the writing of the manuscript.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40273-021-01062-1

Handle.net

Persistent link

Cite this

@article{b946ab5d149a40eb9ad3b61020dfacd1,

title = "Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening",

author = "Edna Keeney and Thom, \{Howard H Z\} and Turner, \{Emma L\} and Martin, \{Richard M\} and Sabina Sanghera",

note = "Funding Information: This work was funded by Cancer Research UK and the UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326, and C18281/A15064, C18281/A24432). SS is funded by a National Institute for Health Research (NIHR) fellowship (PDF-2017-10-008). HT and RMM were supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funding source was not involved in the design of the study, the collection, analysis and interpretation of data or the writing of the manuscript. ",

year = "2021",

month = aug,

doi = "10.1007/s40273-021-01062-1",

language = "English",

volume = "39",

pages = "969--970",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis",

number = "8",

}

TY - JOUR

T1 - Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening

AU - Keeney, Edna

AU - Thom, Howard H Z

AU - Turner, Emma L

AU - Martin, Richard M

AU - Sanghera, Sabina

N1 - Funding Information: This work was funded by Cancer Research UK and the UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326, and C18281/A15064, C18281/A24432). SS is funded by a National Institute for Health Research (NIHR) fellowship (PDF-2017-10-008). HT and RMM were supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funding source was not involved in the design of the study, the collection, analysis and interpretation of data or the writing of the manuscript.

PY - 2021/8

Y1 - 2021/8

U2 - 10.1007/s40273-021-01062-1

DO - 10.1007/s40273-021-01062-1

M3 - Comment/debate (Academic Journal)

C2 - 34273086

SN - 1170-7690

VL - 39

SP - 969

EP - 970

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 8

ER -